

Rona Therapeutics raises \$33 million in Series A

07 April 2022 | News

The funds will be used to advance global discovery and development of RNA therapeutics



China-based startup Rona Therapeutics announces the successful completion of \$33 million Series A financing to advance proprietary delivery platform and initial pipeline of therapeutics. The round was supported by a group of blue-chip investors including Lilly Asia Ventures, CMB International, Platanus, Fontus Capital and Lanting Capital.

Founded in 2021, Rona Therapeutics aims to establish innovative and disruptive RNA medicines with proprietary platform to enable therapeutics with more specific, stable and prolonged effects. The RNA medicines from Rona Therapeutics are modular and programmable modalities targeting disease areas across metabolic diseases, neurological diseases and ophthalmology diseases via different delivery systems. The company is building state-of-the-art facilities to expand nucleic acid synthesis, delivery platform, oligonucleotide chemical modification, RNA biology and manufacturing capability to realize the potential of powerful RNA therapeutics.

"With decades-long exploratory work to decode nucleic acid therapeutics, Rona has the potential to become a leader in RNA medicines to discover and develop transformative therapeutics," said Dr. Roberto Gueriolini, scientific advisor of Rona Therapeutics.